ROSE Foundation
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
ROSE Foundation
May 28, 2024, 00:21 |
Insight
Bursting the Cervical Cancer Bubble with Dr. Farah Gan - ROSE Foundation
ROSE Foundation shared a post on LinkedIn: “Bursting the Cervical Cancer Bubble - Directly from…
May 23, 2024, 14:51 |
Blog
Bursting the Cervical Cancer Bubble with Dr. Yogee - ROSE Foundation
ROSE Foundation shared a post on LinkedIn: “Bursting the Cervical Cancer Bubble - Directly from…
May 17, 2024, 13:09 |
Blog
Bursting the Cervical Cancer Bubble with Dr. Yin Ling Woo - ROSE Foundation
Yin Ling Woo, Professor of Obstetrics and Gynaecology at University of Malaya shared a post…
Apr 9, 2024, 10:27 |
Blog
'We now have the opportunity, if not the responsibility, to eliminate cervical cancer' said by Prof Dr Yin Ling Woo - ROSE Foundation
ROSE Foundation shared a post on LinkedIn: "'We now have the opportunity, if not the responsibility,…
Apr 8, 2024, 16:38 |
Blog
'We now have the opportunity, if not the responsibility, to eliminate cervical cancer' – Dr Yin Ling Woo - ROSE Foundation
ROSE Foundation posted on LinkedIn: " 'We now have the opportunity, if not the responsibility,…
Mar 4, 2024, 17:21 |
Blog
Yin Ling Woo: I've participated in quite a few colposcopy courses this one was one of the best
Yin Ling Woo, Professor of Obstetrics and Gynaecology at University of Malaya, shared on LinkedIn:…
Jan 25, 2024, 17:40 |
Blog
Yin Ling Woo: Malaysia has what it takes to achieve elimination of cervical cancer
Yin Ling Woo, Professor of Obstetrics and Gynaecology at University of Malaya, shared on LinkedIn:…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube